A microsatellite repeat in the promoter of the N-methyl-D-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia

Pharmacogenetics

Volumn 13, Issue 5, 2003, Pages 271-278

  Itokawa, Masanari ^a,b   Yamada, Kazuo ^a   Yoshitsugu, Kiyoshi ^a   Toyota, Tomoko ^a,c,d   Suga, Toshiro ^c   Ohba, Hisako ^a   Watanabe, Akiko ^a   Hattori, Eiji ^a   Shimizu, Hiromitsu ^e   Kumakura, Tetsuo ^f   Ebihara, Mitsuru ^a   Meerabux, Joanne M A ^a   Toru, Michio ^c,d   Yoshikawa, Takeo ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c Shimotakaido Mental Clinic   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e Hokushin General Hospital   (Japan)

^f Haryugaoka Hospital   (Japan)

Author keywords

Case control study; Genotype phenotype correlation; GT repeat; Luciferase assay; PANSS; Postmortem brain; Symptom

Indexed keywords

LUCIFERASE; MICROSATELLITE DNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BINDING ASSAY; CADAVER; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE REPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENOTYPE PHENOTYPE CORRELATION; GRIN2A GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; SCHIZOPHRENIA; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM;

ADULT; AGED; BASE SEQUENCE; DNA PRIMERS; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, N-METHYL-D-ASPARTATE; REFERENCE VALUES; SCHIZOPHRENIA; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 12444281048     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200305000-00006     Document Type: Article

References (29)

1. Gottesmann II. Schizophrenia Genetics: The Origin of Madness. New York, NY: Freeman and Company; 1991.
2. Glenthoj BY, Hemmingsen R. Transmitter dysfunction during the process of schizophrenia. Acta Psychiatr Scand Suppl 1999; 395:105-112.
3. Gainetdinov RR, Mohn AR, Caron MG. Genetic animal models: focus on schizophrenia. Trends Neurosci 2001; 24:527-533.
4. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148:1301-1308.
5. Breier A, Elman I, Clifton A, Pickar D, Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17:141-150.
6. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999; 98:427-436.
7. Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon 1 subunit. J Neurosci 2001; 21:750-757.
8. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987; 1:133-152.
9. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999; 51:7-61.
10. Andersson O, Stenqvist A, Attersand A, von Euler G. Nucleotide sequence, genomic organization, and chromosomal localization of genes encoding the human NMDA receptor subunits NR3A and NR3B. Genomics 2001; 78:178-184.
11. Watanabe M, Inoue Y, Sakimura K, Mishina M. Distinct spatio-temporal distributions of the NMDA receptor channel subunit mRNAs in the brain. Annal NY Acad Sci 1993; 707:463-466.
12. Reich DL, Silvay G. Ketamine: an update on the first 25 years of clinical experience. Can J Anaesth 1989; 36:186-197.
13. Baldridge EB, Bessen HA. Phencyclidine. Emerg Med Clin North Am 1990; 8:541-550.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press; 1994.
15. Costa GL, Bauer JC, McGowan B, Angert M, Weiner MP. Site-directed mutagenesis using a rapid PCR-based method. Methods Mol Biol 1996; 57:239-248.
16. Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, et al. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 1988; 78:121-137.
17. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 1989; 77:231-236.
18. Kay SR. Positive-negative symptom assessment in schizophrenia: psychometric issues and scale comparison. Psychiatr Q 1990; 61:163-178.
19. Kane JM. Schizophrenia, N Engl J Med 1996; 334:34-41.
20. Dewan MJ, Koss M. The clinical impact of reported variance in potency of antipsychotic agents. Acta Psychiatr Scand 1995; 91:229-232.
21. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980; 20:379-382.
22. Faustman WO, Bardgett M, Faull KF, Pfefferbaum A, Csernansky JG. Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients. Biol Psychiatry 1999; 45:68-75.
23. Abi-Saab WM, D'Souza DC, Moghaddam B. Krystal JH. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 1998; 31:104-109.
24. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol Psychiatry 1998; 44:667-674.
25. Yoshikawa T, Watanabe A, Ishitsuka Y, Nakaya A, Nakatani N. Identification of multiple loci linked to the propensity for 'behavioral dispair' in mice. Genome Res 2002; 12: 357-366.
26. Kroemer RT, Koutsilieri E, Hecht P, Liedl KR, Riederer P, Kornhuber J. Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site. J Med Chem 1998; 41:393-400.
27. Gurling H, Chen AC-H. Gene expression in schizophrenia. Am J Psychiatry 2001; 158:1740-1741.
28. Stalling, RL, Ford AF, Nelson, D, Torney DC, Hildebrand CE, Moyzis RK. Evolution and distribution of (GT)n repetitive sequences in mammalian genomes. Genomics 1991; 10:807-815.
29. Rothenburg S, Koch-Nolte F, Rich A, Haag F. A polymorphic dinucleotide repeat in the rat nucleolin gene forms Z-DNA and inhibits promoter activity. Proc Natl Acad Sci USA 2001; 98:8985-8990.